Login to Your Account

Passion for science is paying off in Prothelia partnership

By Marie Powers
Staff Writer

Wednesday, February 26, 2014
Talk about a great Act One. After six years quietly developing Laminin-111, a protein replacement therapy for ultra-rare merosin-deficient congenital muscular dystrophy (MDC1A), privately held Prothelia Inc. snagged leading rare disease firm Alexion Pharmaceuticals Inc. as its first strategic partner earlier this month in a three-way deal with the University of Nevada, Reno, where the technology was developed.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription